Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8149MR)

This product GTTS-WQ8149MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF1A gene. The antibody can be applied in Dry eye (DE) syndrome research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001065.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7132
UniProt ID P19438.1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8149MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4432MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12552MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ4107MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ11443MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ8449MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ8596MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ1978MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ12259MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MRA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW